Literature DB >> 15256283

The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease.

Matthias Heringlake1, Thomas Kox, Orhan Uzun, Barbara Will, Ludger Bahlmann, Stephan Klaus, Sawas Eleftheriadis, Franz Paul Armbruster, Norbert Franz, Ernst Kraatz.   

Abstract

The role of urotensin II (U-II)--a vasoactive, mitogenic, and inotropic, peptide--in the pathophysiology of heart failure is controversial. The present study explores the relationship between plasma U-II immunoreactivity (U-IIIR) and hemodynamics in patients with coronary artery disease (CAD). Thirty-six patients with CAD-3 undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) and 36 medical patients (MED group) with CAD-1 to CAD-3 during right heart catheterization were studied. Significant correlations were observed between pulmonary capillary wedge pressure (PCWP) and U-IIIR--determined by enzyme immunoassay (EIA)--before (rho = 0.83) and after (rho = 0.6) cardiopulmonary bypass in the CABG group. With the exception of the CPB period, CABG patients with increased PCWP before CPB had higher U-II(IR) concentrations throughout the procedure. Significant correlations were observed between U-IIIR, proANP, proBNP, and mean right ventricular pressure (RVPM) in MED patients. No correlation was detectable between U-IIIR and PCWP. However, MED patients with CAD-3 (n = 13) had higher levels of U-IIIR, NTproANPIR (RIA), NTproBNPIR (EIA) and higher cardiac filling pressures than patients with CAD-1 (n = 13). These findings support an association between plasma U-IIIR levels and diastolic myocardial dysfunction in ischemic heart failure. The discrepancies regarding left and right cardiac filling pressures and U-IIIR levels in CABG and MED patients require further evaluation. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256283     DOI: 10.1016/j.regpep.2004.04.012

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  14 in total

1.  Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.

Authors:  San Bao Chai; Xue Min Li; Yong Zheng Pang; Yong Fen Qi; Chao Shu Tang
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 2.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 3.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

4.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 5.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

6.  Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype.

Authors:  Damien Gruson; Michel F Rousseau; Jean-Marie Ketelslegers; Michel P Hermans
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08       Impact factor: 3.738

7.  Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line.

Authors:  Abbas Mohammadi; Ahmad Gholamhoseinian Najar; Amirhosein Khoshi
Journal:  Adv Biomed Res       Date:  2014-01-09

8.  Urotensin-II system in genetic control of blood pressure and renal function.

Authors:  Radoslaw Debiec; Paraskevi Christofidou; Matthew Denniff; Lisa D Bloomer; Pawel Bogdanski; Lukasz Wojnar; Katarzyna Musialik; Fadi J Charchar; John R Thompson; Dawn Waterworth; Kijoung Song; Peter Vollenweider; Gerard Waeber; Ewa Zukowska-Szczechowska; Nilesh J Samani; David Lambert; Maciej Tomaszewski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.

Authors:  Nicolas Bousette; Fazila Chouiali; Eliot H Ohlstein; Stephen A Douglas; Adel Giaid
Journal:  Int J Biomed Sci       Date:  2007-03

10.  Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.

Authors:  Yafeng Li; Sihai Zhao; Yanli Wang; Yulong Chen; Yan Lin; Ninghong Zhu; Huadong Zheng; Min Wu; Daxing Cheng; Yandong Li; Liang Bai; Jianglin Fan; Enqi Liu
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.